Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Shun‐Cang Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6975-3583; OpenAlex author ID A5100577283. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2024: 3 papers · 2025: 4 papers

Papers 7

  1. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202508431↗
  2. Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer. First author DOI 10.1016/j.drup.2025.101240↗
  3. Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy. Co-author DOI 10.1016/j.drup.2025.101292↗
  4. TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. Co-author DOI 10.1158/0008-5472.can-24-4784↗
  5. Targeting the MCP-GPX4/HMGB1 Axis for Effectively Triggering Immunogenic Ferroptosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202308208↗
  6. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis. Co-author DOI 10.1038/s41419-024-07138-y↗
  7. Necroptosis enhances 'don't eat me' signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-024-50450-6↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cheng‐Yu Liao · 7 shared papers, 2024–2025 · strength 1.34
  2. Zuwei Wang · 7 shared papers, 2024–2025 · strength 1.34
  3. Shi Chen · 7 shared papers, 2024–2025 · strength 1.34
  4. Yongding Wu · 5 shared papers, 2024–2025 · strength 0.97
  5. Chengke Xie · 5 shared papers, 2024–2025 · strength 0.96
  6. Ge Li · 4 shared papers, 2024–2025 · strength 0.78
  7. Haoxiang Zhang · 3 shared papers, 2025 · strength 0.60
  8. Hong-Yi Lin · 3 shared papers, 2024–2025 · strength 0.59
  9. Ge Li · 2 shared papers, 2025 · strength 0.40
  10. Yu Pan · 2 shared papers, 2025 · strength 0.40
  11. Yifeng Tian · 2 shared papers, 2024–2025 · strength 0.38
  12. Chun Zhang · 1 shared paper, 2025 · strength 0.20
  13. Jiangzhi Chen · 1 shared paper, 2024 · strength 0.18
  14. Yanling Chen · 1 shared paper, 2024 · strength 0.18
  15. Yanling Chen · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.